Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

All-cause mortality in an Idiopathic Pulmonary Fibrosis (IPF) cohort: retrospective analysis with cardiac QRISK-2

Matthew Watson, Thomas McLellan, Muhunthan Thillai
European Respiratory Journal 2021 58: PA3747; DOI: 10.1183/13993003.congress-2021.PA3747
Matthew Watson
1Cambridge University, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mw696@cam.ac.uk
Thomas McLellan
2Royal Papworth Hospital, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhunthan Thillai
2Royal Papworth Hospital, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: Patients with IPF live longer with anti-fibrotic therapy but have high cardiovascular risk. This may increase mortality independent of the severity of their lung disease.

The QRISK-2 score is validated in the UK. Using demographic (age, smoking history, ethnicity) and personal risk-factors (presence of hypercholesterolaemia/hypertension/renal/diabetic disease) it predicts the risk of a primary cardiovascular event within 10 years. A score of ≥10% indicates need for primary prevention and ≥20% is high risk.

Aim: Assess the relationship between QRISK-2, IPF severity (TLCO, FVC and GAP-score) at diagnosis and all-cause mortality in IPF patients from a single UK-centre.

Methods: Data for the study was taken from patient records. Individuals were followed-up until death or a cardiovascular event.

Results: Mean follow up for 248 patients (table 1) was 3.1 years. 141 patients died. There were 11 cardiovascular events.

Mean QRISK score was 27.0% (SD 12.3). 70% (n=172) had a QRISK-2 >20%. There was no survival difference when patients were stratified by diagnosis TLCO, FVC or GAP-stage. Patients with a QRISK<20% at diagnosis survived longer than those with a QRISK>20% (fig 1).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Conclusion: Multimorbidity in IPF patients affects mortality. The QRISK-2 may be a useful marker of this. TLCO and FVC at diagnosis did not predict mortality. The effect of anti-fibrotic therapy may have been contributory.

  • Idiopathic pulmonary fibrosis

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3747.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
All-cause mortality in an Idiopathic Pulmonary Fibrosis (IPF) cohort: retrospective analysis with cardiac QRISK-2
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
All-cause mortality in an Idiopathic Pulmonary Fibrosis (IPF) cohort: retrospective analysis with cardiac QRISK-2
Matthew Watson, Thomas McLellan, Muhunthan Thillai
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3747; DOI: 10.1183/13993003.congress-2021.PA3747

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
All-cause mortality in an Idiopathic Pulmonary Fibrosis (IPF) cohort: retrospective analysis with cardiac QRISK-2
Matthew Watson, Thomas McLellan, Muhunthan Thillai
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3747; DOI: 10.1183/13993003.congress-2021.PA3747
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
  • Evaluation of three dyspnea questionnaires in the progression of Interstitial Lung Diseases
  • IPF cluster analysis highlights diagnostic delay and cardiovascular comorbidities association with outcome
Show more Idiopathic interstitial pneumonias

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society